Holzkirchen, October 13, 2014 – Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for the global generics industry, has awarded the company with “Biosimilars Initiative of the Year”, for its file acceptance of G-CSF (filgrastim) in the US. Sandoz also achieved top-three podium positions in the Company of the Year; Company of the Year – Americas; and Innovation of the Year Awards categories.

On July 24, Sandoz, announced that the FDA accepted its application for filgrastim, making Sandoz the first company …